Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Mar
11
Today In Oncology
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden
2026 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
Prostate Cancer: Low Testosterone Levels May Be Associated With Increased Risk of Progression During Surveillance
Stanford Names Leader for Drug Development and Precision Oncology
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo